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Purpose or Objective: Based on poor results using 
hypofractionated adjuvant radiotherapy (RT) of early breast 
cancer (BC) 50 Gy/25 fr. has been Danish Breast Cancer 
Group (DBCG) standard since 1982. Results from the UK and 
Canada stimulated a renewed interest in hypofractionation, 
and the non-inferiority DBCG HYPO trial was initiated. The 
hypothesis was that 40 Gy/15 fr (2.67 Gy/fr, 3 weeks) does 
not result in more grade 2-3 breast induration than 50 Gy/25 
fr (2.0 Gy/fr, 5 weeks) 3 years post RT. 
 
Materials and Methods: From 2009-2014 1868 patients >40 
years operated with breast conservation for early pT1-2 pN0-
1(mic) BC (n=1617) or DCIS (n=251) were enrolled irrespective 
of breast size, systemic therapy and boost, and randomized 
50 Gy/25 fr vs. 40Gy/15 fr. Strata were institution, breast 
size (≤ 600 ml vs. > 600 ml), systemic therapy and boost. The 
primary endpoint was grade 2-3 induration 3 years post RT, 
secondary endpoints were other normal tissue responses, 
genetic risk profile for RT-induced fibrosis and recurrences. 
ClinicalTrial NCT00909818. 
 
Results: 942 pts (50.4%) were assigned to the 50 Gy group 
and 926 (49.6%) to the 40 Gy group. Median age was 59 years 
(range 39-83). Median follow up was 3 years. The analysis was 
by intention to treat. Results are actuarial 3 year rates using 
morbidity in 1801 pts 1 yr post RT as baseline. 1086 pts (60%) 
had 3 year scores of morbidity and the rate of grade 2-3 
induration was 12.2%±1%. Grade 2-3 induration was seen in 
the 50 Gy group in 119 out of 904 pts with the rate 
14.2%±1.4%, and in the 40 Gy group in 97 out of 897 pts, the 
rate being 10.1% ±1%, representing a HR 1.27 (95% CI 0.97-
1.66), p=0.08. 859 pts (48%) had small breasts with a rate of 
grade 2-3 induration of 9.8%±1% compared to 14.3%±1% 
among 942 pts with large breasts, HR 1.56, (95% CI 1.18-
2.05), p=0.001. Among the 653 pts (36%) treated with 
chemotherapy (CT) the rate of grade 2-3 induration was 
12.4%±1%, whilst in the 1148 pts with no CT the rate was 
11.8%±2%, HR 0.98 (95% CI 0.74-1.30), p=0.90. In 423 pts 
(23%) treated with sequential boost (10-16 Gy/5-8 fr) the 
rate of grade 2-3 induration was 12.4%±1% compared to 
12.1%±1% among 1378 pts with no boost, HR 0.93 (95% CI 
0.67-1.29), p=0.65. Multivariate analysis using grade 2-3 
induration at 3 yr as endpoint and including 
hypofractionation, breast size, chemotherapy and boost 
identified large breast size as the only independent risk 
factor. Overall the 3 yr risk of loco-regional recurrence was 
0.3%±0.1%. In the 50Gy / 40 Gy group loco-regional 
recurrence was reported in 2 pts / 4 pts, distant failure 4 pts 
/ 3 pts, new contralateral cancer or DCIS 2 pts / 3 pts.  
 
Conclusion: Moderately hypofractionated whole breast 
irradiation in early node-negative BC or DCIS does not result 
in more grade 2-3 induration compared to normofractionated 
therapy. Large breast size is an independent risk factor for 
developing induration. The 3 yr loco-regional recurrence risk 
is very low. 
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Purpose or Objective: We report preliminary results from a 
Bayescian randomized trial of IMRT vs. PSPT , both given with 
concurrent chemotherapy, for locally advanced (stage II-IIIB) 
NSCLC. The purpose of the trial was to assess and compare 
the incidence and time to development of treatment failure 
defined as (1) grade ≥3 pneumonitis or (2) local failure, 
whichever occurred first in 12 month. 
 
Materials and Methods: The sample size for this trial (n=150) 
was based on the assumption that incidence would be log-
normally distributed and that IMRT would produce event 
rates of 30% at 6 mo and 40% at 12 mo, and PSPT would 
reduce the event rate by 10%. The Bayescian design was 
chosen so that more patients will be randomly allocated to 
the more effective of the two treatments. All patients must 
have been candidates for concurent chemoradiation, and all 
underwent 4D CT-based treatment planning. An IMRT and a 
PSPT plan were created for each patient. Patients were 
eligible for randomization only if both plans satisfied normal 
tissue constraints at the same prescription dose (74 Gy (RBE) 
if achievable , otherwise 66 Gy (RBE), where RBE is 1 for 
photons and 1.1 for protons) 
 
Results: Total 147 patients who were randomized to IMRT 
(n=90) or PSPT (n=57) and treated according to randomization 
were included for this analysis. Demographic characteristics 
were well balanced between the two arms. The GTV and PTV 
volumes were bigger in the PSPT arm though the difference 
was not statisically significant. More patients in PSPT arm 
received higher tumor dose. Patients in PSPT arm had larger 
volume of the lung receiving ≥30 -80 Gy (RBE) compared with 
IMRT patients, presumably due to the larger target volume 
and 3D nature of PSPT. The incidence of protocol failure at 
12 month were 20.7%, 15.6%, and 24.6% in all, in IMRT, and in 
PSPT patients, respectively. The median failure free survival 
times were 67.6, 67.6, and 69. 8 months in all, in IMRT, and 
in PSPT patients, respectively. Total of 12 patients developed 
grade ≥3 or higher RP, 6 in each arm. Two of the 6 patients 
had grade 5 RP in IMRT arm. The incidences of grade ≥3 RP 
were 8.7%, 7.2%, and 11.0% in all, in IMRT, and in PSPT 
patients, respectively. 
 
Conclusion: Considerably fewer events occurred in the 
evaulable randomized patients than were expected from 
historical experience. No statistical differences were found 
between IMRT vs. PSPT in the incidence of treatment failure, 
grade ≥3 pneumonitis, or local failure. Future analyses will 
involve comparing data from CT and PET images, blood 
samples and symptoms and their correlations with dose 
distributions to clarify factors affecting outcomes and to 
determine how physical and biological uncertainties affect 
proton dose distributions. *Supported in part by NCI grants 
P01 CA021230 and U19 CA021239. 
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Purpose or Objective: The role of prophylactic cranial 
irradiation (PCI) in limited disease (LD) small-cell lung cancer 
(SCLC) has proven to significantly decrease the incidence of 
S66                                                                                     ESTRO 35 2016 
 _____________________________________________________________________________________________________ 
brain metastases (BMs) with only modest improvement of 
overall survival. 
Materials and Methods: To evaluate the impact of PCI on 
survival we reviewed 179 LD SCLC patients treated with 
definitive chemoradiotherapy (CRT) in the concurrent or 
sequential setting. PCI was applied in the partial and 
complete responders exclusively provided contrast-enhanced 
cranial magnetic resonance imaging (cMRI) before and after 
primary treatment showed no signs of occult BMs. Correlation 
between PCI and time to progression (TTP) as well as overall 
survival (OS) was analysed. Kaplan-Meier analysis, uni- and 
multivariate Cox regression were used to describe survival 
within subgroups defined by treatment response and 
application of PCI. 
 
Results: Concurrent and sequential chemoradiotherapy CRT 
was applied in 71 (40%) and 108 (60%) patients, respectively. 
In 58 (32%) patients metachronous BMs were detected. PCI 
was applied in 71 (39%) patients. 15 patients developed BMs 
after PCI. Median TTP and OS in responders treated with PCI 
were 812 and 801 compared to 355 (range: 284 - 456) (p < 
0.0001, log-rank test) and 385 (range: 318 – 452) (p < 0.0001, 
log-rank test) days in the rest of the patient cohort. In 
multivariate analysis, application of PCI in treatment 
responders comprehensively staged with cMRI was a variable 
that significantly correlated with TTP (HR 2.16 CI HR 1.37-
3.42, p < 0.001) and OS (HR 1.89 CI HR 1.37-2.63, p < 0.0001) 
after adjustment of other patient- and treatment-related 
factors. 
 
Conclusion: In this LD SCLC patient cohort comprehensively 
staged with cMRI, achievement of maximum treatment 
response and application of PCI significantly affects time to 
progression and overall survival. 
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Purpose or Objective: Preoperative chemoradiotherapy 
(CRT) has been established as the standard treatment for T3-
4 rectal cancers. In a phase II trial, we reported limited 
toxicity and excellent local control using image-guided and 
intensity-modulated RT (IG-IMRT) with a simultaneous 
integrated boost (RTSIB) instead of concomitant 
chemotherapy. The present multicentric randomized trial 
compares this strategy to CRT. In addition, the neutrophil-
to-lymphocyte ratio (NLR) and C-reactive protein (CRP) were 
examined as a prognostic immunoscore in a subset of 
patients. 
 
Materials and Methods: cT3-4 rectal cancer patients were 
randomly assigned to receive either preoperative IG-IMRT 
46Gy/23 fractions plus capecitabine 825 mg/m2 twice daily 
(CRT-arm) or IG- IMRT 46Gy/23 fractions with a SIB to the 
rectal tumor up to a total dose of 55.2 Gy (RTSIB- arm). 
Metabolic tumor activity reduction, by measuring the 
percentage of SUVmax difference (Response Index = RI) on 
sequential 18-fluorodeoxyglucose positron emission 
tomography (FDG-PET), was the primary endpoint. We 
assessed whether RTSIB was non-inferior to CRT with a non-
inferiority margin of -10% for RI. 
 
Results: A total of 174 patients were randomly assigned to 
the CRT-arm (n=89) or RTSIB- arm (n=85). A consort flow 
diagram is presented in Figure 1. The RI difference between 
RTSIB and CRT was -2.9% (95% CI, -10.1% to 4.3%). The ypCR 
rate was 24% with CRT compared to 14% with RTSIB (p=0.13). 
There was no significant difference in sphincter preservation 
(75% vs 68%, p=0.29). The R0 resection rate was 98% in the 
CRT-arm and 97% in the RTSIB-arm. Acute grade 3 toxicity 
was 6% and 4% in the CRT- and RTSIB-arm, respectively. A 
detailed analyses of early adverse events is shown in Table 1. 
The highest quartiles of NLR and CRP identified high-risk 
patients in terms of disease free and overall survival. 
 
 
 
 
Conclusion: Preoperative CRT is well tolerated when IG-IMRT 
is used. RTSIB represents an attractive alternative to CRT for 
patients with a contra-indication for chemotherapy. The 
immunological landscape of colorectal cancer shapes novel 
possibilities for risk assessment. 
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